Lizhu Pharma has been granted china's interest in THE same source Kang Pharmaceutical ROS1/NTRK/ALK multi-kinase inhibitors.

On August 31, Lizhu Pharmaceuticals and Tongyuan Kang Pharmaceuticals announced the signing of a Patent Transfer and Technology Exclusive License Agreement.
Under the agreement, Lizhu Pharma has exclusive development and commercial rights to the latter's TY2136b project (a ROS1/NTRK/ALK multi-kinase small molecule inhibitor) and its related patents in China, including Hong Kong, Macau and Taiwan.
preclinical research and development fees, down payments and milestone payments for this transaction amounted to RMB159 million.
ros1 positive accounts for about 2% of patients with non-small cell lung cancer (NSCLC).
Cancer patients caused by the NTRK gene fusion mutation account for about 0.5%-1% of the number of NSCLC patients, in addition to the gene fusion can also cause a variety of cancers, including appendix cancer, breast cancer, bile tube cancer, colorectal cancer, gastrointestinal mesothelioma (GIST) and many other 17 kinds of solid tumors.
ALC positive accounts for about 5%-8% of the number of NSCLC patients, and after ALC inhibitor treatment, especially second-generation ALC inhibitor treatment, a large number of G1202R drug-resistant mutations are produced.
agreement, Lizhu Pharmaceuticals will receive exclusive development and commercial rights for the TY-2136b project in China.
Lizhu Pharmaceuticals shall pay the corresponding preclinical research and development fees according to the progress of the research and development of the licensed project, totalling not more than RMB22 million, and the excess shall be borne by Tongyuan Kang Pharmaceuticals itself.
the agreement came into effect, Lizhu Pharmaceuticals should first pay a down payment of RMB 8 million to Tongyuan Kang Pharmaceuticals.
In addition, in the licensing project to complete GLP toxicology research, access to the China National Drug Administration (NMPA) IND filing acquiescence, complete the first phase 1 clinical first patient into the group, complete the first phase 2 clinical first patient into the group, complete the first 3 During the phase of the first clinical patient's entry into the group, the first adaptive disease obtained NMPA approval listing and each new adaptive disease approved for listing stage, Lizhu Pharmaceuticals shall pay the corresponding milestone money to the same source Kang Pharmaceuticals, a total of not more than 129 million yuan.
the same time, Lizhu Pharmaceuticals should pay the same source Kang Pharmaceuticals not less than 6% of net sales of floating sales.
: 1. Lizhu Pharmaceutical Voluntary Announcement - Signing Patent Transfer and Technology Exclusive License Agreement. Retrieved Aug 31, 2020, from the same source Kang Pharmaceuticals and Lizhu Pharmaceuticals reached a multi-target kinase inhibitor China equity deal. Retrieved Aug 31, 2020, From.